Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

This study has been completed.
Sponsor:
Collaborator:
CTI Clinical Trial and Consulting Services
Information provided by (Responsible Party):
Veloxis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00496483
First received: July 2, 2007
Last updated: June 25, 2015
Last verified: June 2015
  Purpose

A three sequence, open-label, multi-center, prospective, study in stable kidney transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.


Condition Intervention Phase
Renal Failure
Drug: LCP Tacro (tacrolimus)
Drug: Prograf
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day

Resource links provided by NLM:


Further study details as provided by Veloxis Pharmaceuticals:

Primary Outcome Measures:
  • Evaluation of Steady State Tacrolimus Trough Levels (C24). [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.

  • Evaluation of Steady State Tacrolimus Exposure (AUC 0-24). [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    Patients had a baseline AUC measured (0 to 24 hours) at day 7 before conversion to LCP-Tacro.

  • Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24). [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, a trough level (C24) was measured.

  • Evaluation of Steady State Tacrolimus Exposure (AUC 0-24). [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, AUC was measured (0 to 24 hours).


Secondary Outcome Measures:
  • Tacrolimus Pharmacokinetics (Cmax and Cavg) Was Measured at Day 21. [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Cmax and Cavg was measured at day 21 (Cmin was measured as part of the primary outcome).

  • Tacrolimus Pharmacokinetics (Tmax) Was Measured at Day 21. [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Tmax was measured at day 21 (Cmin was measured as part of the primary outcome).

  • Tacrolimus Pharmacokinetics (Fluctuation and Swing) Was Measured at Day 21. [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Degree og fluctuation and degree of swing was measured at day 21 (Cmin was measured as part of the primary outcome).

  • Tacrolimus Pharmacokinetics (Cmax and Cavg) Was Measured at Day 7. [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    Cmax and Cavg was measured at baseline day 7 (Cmin was measured as part of the primary outcome).

  • Tacrolimus Pharmacokinetics (Tmax) Was Measured at Day 7. [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    Tmax was measured at baseline day 7 (Cmin was measured as part of the primary outcome).

  • Tacrolimus Pharmacokinetics (Fluctuation and Swing) Was Measured at Day 7. [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    Degree og fluctuation and degree of swing was measured as baseline at day 7 (Cmin was measured as part of the primary outcome).

  • Safety Evaluation [ Time Frame: 52 days ] [ Designated as safety issue: Yes ]
    A combination of deaths, graft failure and biopsy proven acute rejections (BPAR) was used to evaluate the safety.


Enrollment: 60
Study Start Date: July 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: LCP-Tacro (tacrolimus)
Experimental: LCP Tacro; investigational product LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
Drug: LCP Tacro (tacrolimus)

Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.

Other Names:

Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.

Other Name: tacrolimus
Drug: Prograf

Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.

Other Names:

Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.

Other Name: Tacrolimus

Detailed Description:

A three sequence, open-label, multi-center, prospective, study in stable kidney transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.

Stable kidney transplant patients who fulfill all I/E criteria will be enrolled and kept on Prograf for 7 days. Following a 24-hour PK study on Day 7 to determine pharmacokinetics for Prograf, all patients will be converted to once daily LCP-Tacro for 7 days with no dose changes allowed. On Day 14 and Day 21 a 24-hour LCP-Tacro PK study will be performed. On Day 22 patients will be converted back to their original twice daily dose of Prograf for a safety follow-up period of 30 days ending with a safety assessment on day 53.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women 18-65 years of age who are recipients of a renal transplant at least 6 months prior to enrollment
  • Patients on oral Prograf therapy as part of their maintenance immunosuppression therapy, with stable doses and trough levels of tacrolimus of 7-12 ng/mL for at least two weeks prior to enrollment.
  • Patients maintained on concurrent immunosuppression with mycophenolate mofetil (MMF, CellCept) or mycophenolic acid delayed-release tablets (Myfortic), with stable doses for at least two weeks prior to enrollment
  • Patients with serum creatinine < 2.0mg/dL prior to enrollment
  • Able to swallow study medication
  • Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study
  • Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication
  • Patients who successfully pass a drug screen

Exclusion Criteria:

  • Recipients of any transplanted organ other than a kidney
  • White blood cell count < 2.8 x 10^9 /L
  • Patients who are receiving a total dose of Prograf for 24 hours < 3mg
  • Patients unable or unwilling to provide informed consent
  • Pregnant or nursing women
  • Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception
  • Administration of other investigational agent in the three months prior to enrollment
  • Patient receiving any drug interfering with tacrolimus metabolism
  • Patients who have taken sirolimus within the past three months prior to screening
  • Patient with an episode of acute cellular requiring antibody therapy within the 6 months prior to enrollment
  • Patient treated for acute cellular rejection within the 30 days prior to enrollment
  • Patient who is HCV negative and has received an HCV positive (HCV RNA by PCR or HCV antibody) donor kidney
  • Patient has a current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully
  • Patient has uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives
  • Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus
  • Patient will require therapy with any immunosuppressive agent other than those prescribed in the study
  • Patient has a known hypersensitivity to corticosteroids, mycophenolate mofetil, mycophenolic acid or tacrolimus
  • Patient has any form of current substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00496483

Locations
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
United States, Texas
Methodist Hospital Houston
Houston, Texas, United States, 77030
Sponsors and Collaborators
Veloxis Pharmaceuticals
CTI Clinical Trial and Consulting Services
Investigators
Study Director: Alan Glicklich, MD Veloxis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Veloxis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00496483     History of Changes
Other Study ID Numbers: LCP-Tacro 2011
Study First Received: July 2, 2007
Results First Received: May 29, 2014
Last Updated: June 25, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Veloxis Pharmaceuticals:
Tacrolimus
Pharmacokinetics
Kidney Transplantation

Additional relevant MeSH terms:
Tacrolimus
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 27, 2015